DECISA Project (DErmatology Clinics in Italy: Survey on Alitretinoin): A real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczema.

Szczegóły
Abstrakt

Tytuł:: DECISA Project (DErmatology Clinics in Italy: Survey on Alitretinoin): A real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczema.
Autorzy:: Ferrucci S; U.O.C. Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
Persichini P; U.O.C. Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
Gola M; SAS di Dermatologia Allergologica e Professionale-AUSL Toscana Centro e Università degli Studi di Firenze, Florence, Italy.
Scandagli I; SAS di Dermatologia Allergologica e Professionale-AUSL Toscana Centro e Università degli Studi di Firenze, Florence, Italy.
Pigatto P; UO Dermatologia IRCCS Ospedale Galeazzi & Università degli Studi di Milano, Milan, Italy.
Legori A; UO Dermatologia IRCCS Ospedale Galeazzi & Università degli Studi di Milano, Milan, Italy.
Musumeci ML; Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy.
Micali G; Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy.
D'Agata E; Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy.
Schena D; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Azzolini A; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Gallo R; Clinica Dermatologica-DISSAL, Università di Genova e Ospedale Policlinico San Martino-IRCCS, Genoa, Italy.
Trave I; Clinica Dermatologica-DISSAL, Università di Genova e Ospedale Policlinico San Martino-IRCCS, Genoa, Italy.
Cristaudo A; UOSD Dermatologia MST, Ambientale, Tropicale e Immigrazione Istituto Dermatologico San Gallicano (IRCCS), Rome, Italy.
Patruno C; Unit of Dermatology, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Napolitano M; Department of Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy.
Zucca M; Dermatologic Clinic, Hospital S. Giovanni di Dio, Cagliari, Italy.
Piras V; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Stingeni L; Dermatology Section, Department of Medicine, University of Perugia, Italy.
Bianchi L; Dermatology Section, Department of Medicine, University of Perugia, Italy.
Corazza M; Sezione di Dermatologia, Dipartimento di Scienze Mediche, Università di Ferrara, Ferrara, Italy.
Zedde P; Sezione di Dermatologia, Dipartimento di Scienze Mediche, Università di Ferrara, Ferrara, Italy.
Foti C; Dipartimento di Scienze Biomediche ed Oncologia Umana, Clinica Dermatologica, Bari, Italy.
Romita P; Dipartimento di Scienze Biomediche ed Oncologia Umana, Clinica Dermatologica, Bari, Italy.
Cannavò SP; Dipartimento di Medicina Clinica e Sperimentale-Dermatologia, Università di Messina, Messina, Italy.
Guarneri F; Dipartimento di Medicina Clinica e Sperimentale-Dermatologia, Università di Messina, Messina, Italy.
Źródło:: Dermatologic therapy [Dermatol Ther] 2021 May; Vol. 34 (3), pp. e14911. Date of Electronic Publication: 2021 Mar 09.
Typ publikacji:: Journal Article; Multicenter Study
Język:: English
Imprint Name(s):: Publication: July/Aug. 2008- : Hoboken, NJ : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard, c1996-
MeSH Terms:: Dermatologic Agents*/adverse effects
Dermatology*
Eczema*/diagnosis
Eczema*/drug therapy
Hand Dermatoses*/diagnosis
Hand Dermatoses*/drug therapy
Adult ; Alitretinoin ; Chronic Disease ; Female ; Humans ; Italy ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Tretinoin/adverse effects
References:: Coenraads PJ, Nater JP, van der Lende R. Prevalence of eczema and other dermatoses of the hands and arms in The Netherlands. Association with age and occupation. Clin Exp Dermatol. 1983;8:495-503.
Ayala F, Nino M, Fabbrocini G, et al. Quality of life and contact dermatitis: a disease-specific questionnaire. Dermatitis. 2010;21:84-90.
Holden CA, Berth-Jones J. Eczema, lichenification, prurigo and erythroderma: hand eczema. In: Burns T, Breathnach SM, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology. 7th ed. Oxford: Blackwell Scientific Publications; 2004:17.1-17.55.
Diepgen TL, Andersen KE, Brandao FM, et al. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. Br J Dermatol. 2009;160:353-358.
Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis II. Contact Dermatitis. 2008;58:335-339.
Johansen JD, Hald M, Andersen BL, et al. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact Dermatitis Group. Contact Dermatitis. 2011;65:13-21.
Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14:267-284.
Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population- based study. Br J Dermatol. 2009;161:397-403.
Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17:437-443.
Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28:351-362.
Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92:251-255.
English J. Alitretinoin for the treatment of chronic eczema of the hand. Clin Med Insights Dermatol. 2011;4:7-16.
Dirschka T, Reich K, Bissonnette R, Maares J, Brown T, Diepgen TL. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Clin Exp Dermatol. 2011;36:149-154.
King T, McKenna J, Alexandroff AB. Alitretinoin for the treatment of severe chronic hand eczema. Patient Prefer Adherence. 2014;8:1629-1634.
Gola M, D'Erme AM, Milanesi N, Marmugi L. Effects of alitretinoin on quality of life of patients having chronic hand eczema: an observational study. Dermatitis. 2013;24:166-169.
Gola M, Milanesi N, D'Erme AM. Clinical evaluation and assessment of the therapeutic efficacy of alitretinoin in a group of patients with chronic hand eczema refractory to topical steroid therapy. G Ital Dermatol Venereol. 2014;149:435-439.
Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808-817.
Haukoos JS, Newgard CD. Advanced statistics: missing data in clinical research: part 1-an introduction and conceptual framework. Acad Emerg Med. 2007;14:662-668.
Kubica E, Ezzedine K, Lalanne N, Dartial Y, Taieb A, Milpied B. Oral alitretinoin in chronic refractory hand eczema: a "real life" case-series of 12 patients. Eur J Dermatol. 2011;21:454-456.
Halioua B, Paul C, Berbis P, et al. Efficacy and safety of oral alitretinoin as treatment for chronic hand eczema in France: a real-life open-label study. Eur J Dermatol. 2019;29:59-66.
Urrutia S, Roustan G, Plazas MJ, Armengol S, Paz S, Lizan L. Oral alitretinoin in the treatment of severe refractory chronic hand eczema in the Spanish National Health System: description and analysis of current clinical practice. Actas Dermosifiliogr. 2016;107:142-148.
Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology. 1999;199:308-312.
Gulliver WP, Baker KA. Effective treatment of chronic hand dermatitis with 36 continuous months of alitretinoin administration: report of three cases. J Cutan Med Surg. 2012;16:267-271.
Kim HJ, Lee SK, Baek J, Roh JY. Use of alitretinoin in moderate to severe chronic hand eczema: a real-world experience in Korea. Dermatol Ther. 2019;32:e12980.
Ham K, Maini P, Gooderham MJ. Real-world experience with alitretinoin in a community dermatology practice setting in patients with chronic hand dermatitis. J Cutan Med Surg. 2014;18:332-336.
Crowley EL, Sayeau RL, Gooderham MJ. An update on the use of alitretinoin for chronic hand dermatitis in a dermatology practice setting. J Cutan Med Surg. 2018;22:102-103.
Thaçi D, Augustin M, Westermayer B, Kamps A, Hennig M. Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. J Dermatol Treat. 2016;27:577-583.
Augustin M, Thaçi D, Kamps A. Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA real-world study. J Dtsch Dermatol Ges. 2016;14:1261-1270.
Gallo R, Guarneri F, Corazza M, et al. Role of occupational and recreational sun exposure as a risk factor for keratinocytic non-melanoma skin cancers: an Italian multicentre case-control study. G Ital Dermatol Venereol. 2020. https://doi.org/10.23736/S0392-0488.20.06699-7.
Contributed Indexing:: Keywords: alitretinoin; chronic hand eczema; real-life study; retrospective study
Substance Nomenclature:: 0 (Dermatologic Agents)
1UA8E65KDZ (Alitretinoin)
5688UTC01R (Tretinoin)
Entry Date(s):: Date Created: 20210223 Date Completed: 20210630 Latest Revision: 20210630
Update Code:: 20240105
DOI:: 10.1111/dth.14911
PMID:: 33619833
: Czasopismo naukowe

Pełny tekst

Alitretinoin is the only systemic agent approved to treat moderate-severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids. No nationwide Italian data regarding real-life efficacy, safety, and tolerability of treatment are available. The DECISA project (DErmatology Clinics in Italy: Survey on Alitretinoin) retrospectively examined data from a registry including 15 Dermatology Clinics authorized to prescription of alitretinoin for CHE patients. Disease severity was assessed at baseline, and after 3 and 6 months of treatment, using the 5-point Physician Global Assessment (PGA) and the modified Total Lesion-Symptoms-Severity (mTLSS) scores. Between November 2010 and July 2018, data of 248 male and 190 female patients (mean age 49.71 ± 13.20 years) treated with alitretinoin were collected. Of them, 43.2% had irritant contact dermatitis, 22.2% allergic contact dermatitis, 18.0% atopic dermatitis, 16.7% mixed (irritant/allergic) type of eczema. At 3 months, the 420 re-evaluated patients showed significantly reduced mTLSS and PGA (P < .0000001 vs baseline for both); PGA was clear/almost clear in 35.6% of cases. At 6 months, the 341 re-evaluated patients showed significant (P < .0000001) improvement of mTLSS and PGA vs baseline and 3 months (PGA clear/almost clear: 41.4%). Relapses occurred in 125 patients; 58 underwent an additional course of alitretinoin, with similarly good results. No relevant safety issues were reported; 86 patients experienced adverse effects, which forced 40 to prematurely stop treatment. The DECISA project results confirm the real-life efficacy, safety and tolerability of alitretinoin in the treatment of moderate to severe CHE refractory to standard topical therapies.
(© 2021 Wiley Periodicals LLC.)

Informacja